Rhenman & Partners Asset Management AB Purchases 6,500 Shares of IQVIA Holdings Inc. $IQV

Rhenman & Partners Asset Management AB increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 50.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 19,500 shares of the medical research company’s stock after purchasing an additional 6,500 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in IQVIA were worth $3,704,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Angeles Wealth Management LLC bought a new stake in IQVIA during the third quarter worth $215,000. Blair William & Co. IL raised its stake in shares of IQVIA by 7.6% during the 3rd quarter. Blair William & Co. IL now owns 7,151 shares of the medical research company’s stock worth $1,358,000 after purchasing an additional 502 shares during the period. First Trust Advisors LP boosted its holdings in shares of IQVIA by 22.2% in the 3rd quarter. First Trust Advisors LP now owns 112,426 shares of the medical research company’s stock worth $21,354,000 after buying an additional 20,411 shares during the last quarter. Neo Ivy Capital Management grew its position in IQVIA by 1,065.5% during the third quarter. Neo Ivy Capital Management now owns 12,436 shares of the medical research company’s stock valued at $2,362,000 after buying an additional 11,369 shares during the period. Finally, Foresight Global Investors Inc. bought a new position in IQVIA during the third quarter valued at about $327,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on IQV shares. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Mizuho set a $215.00 price objective on IQVIA in a research note on Monday, February 23rd. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. UBS Group dropped their price target on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Finally, Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $231.13.

IQVIA Trading Down 2.2%

IQVIA stock opened at $174.56 on Friday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The stock has a market cap of $29.62 billion, a P/E ratio of 22.21, a PEG ratio of 1.68 and a beta of 1.39. The firm’s fifty day moving average price is $207.22 and its 200-day moving average price is $207.47.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same quarter last year, the company earned $3.12 earnings per share. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.